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Abstract: Facioscapulohumeral muscular dystrophy (FSHD) has been classified as an autosomal dominant 
myopathy, linked to rearrangements in an array of 3.3 kb tandemly repeated DNA elements (D4Z4) located at 
the 4q subtelomere (4q35). For the last 20 years, the diagnosis of FSHD has been confirmed in clinical 
practice by the detection of one D4Z4 allele with a reduced number (≤8) of repeats at 4q35. Although wide 
inter- and intra-familial clinical variability was found in subjects carrying D4Z4 alleles of reduced size, this DNA 
testing has been considered highly sensitive and specific. However, several exceptions to this general rule 
have been reported. Specifically, FSHD families with asymptomatic relatives carrying D4Z4 reduced alleles, 
FSHD genealogies with subjects affected with other neuromuscular disorders and FSHD affected patients 
carrying D4Z4 alleles of normal size have been described. In order to explain these findings, it has been 
proposed that the reduction of D4Z4 repeats at 4q35 could be pathogenic only in certain chromosomal 
backgrounds, defined as “permissive” specific haplotypes. However, our most recent studies show that the 
current DNA signature of FSHD is a common polymorphism and that in FSHD families the risk of developing 
FSHD for carriers of D4Z4 reduced alleles (DRA) depends on additional factors besides the 4q35 locus. These 
findings highlight the necessity to re-evaluate the significance and the predictive value of DRA, not only for 
research but also in clinical practice. Further clinical and genetic analysis of FSHD families will be extremely 
important for studies aiming at dissecting the complexity of FSHD. 
Keywords: D4Z4 reduced allele, diagnostic criteria, facioscapulohumeral muscular dystrophy, genetic counseling, 
genetic heterogeneity, genotype-phenotype correlation, molecular test, muscle disease. 
INTRODUCTION 
 Facioscapulohumeral muscular dystrophy (FSHD, 
OMIM #158900) is the third most common form of 
hereditary myopathy with a prevalence of 1 in 20.000 
[1]. The disease is characterized by progressive 
atrophy and weakness of a highly selective set of 
muscle groups. Before the finding of D4Z4 reduced 
alleles (DRA) at 4q35, which have been considered 
pathognomonic for disease, the diagnosis and 
counseling of FSHD families were entirely based on 
clinical evidence and family history. Over the years, 
DNA testing for FSHD has been considered highly 
sensitive and specific [2, 3]. Thus there has been a 
tendency to associate clinical findings and molecular 
data, even when the phenotype did not completely fulfill 
the clinical criteria of FSHD. However, the specificity 
and the sensitivity of DNA testing in FSHD have come 
into question since it was observed that 1) 3% of 
 
 
*Address correspondence to this author at the Miogen Lab, 
Department of Life Sciences, University of Modena and Reggio 
Emilia, via Giuseppe Campi, 287, 41125 Modena, Italy; Tel: +39 059 
2055441; Fax: +39 059 2055426; E-mail: rossella.tupler@unimore.it 
healthy subjects from the general population carry DRA 
[4-7] and 2) 20% of FSHD probands do not carry DRA 
[7-10]. These clinical and molecular studies show that 
FSHD is a more complex disorder than previously 
thought. Therefore the current molecular signature is 
insufficient to diagnose FSHD and has to be carefully 
re-evaluated as predictor of disease outcome. 
Moreover, a wide range of myopathic phenotypes have 
been observed in subjects carrying DRA, indicating that 
a careful clinical diagnosis and molecular 
characterization of each family should be performed to 
determine the significance of DRA. It is indeed possible 
that the lack of specificity of DRA might have led to 
biased interpretations of clinical observations. 
Additionally, genetic heterogeneity must be considered 
in FSHD families in which no DRA segregates. An 
unbiased analysis of such genealogies as well as in 
families with no clear autosomal dominant inheritance 
might allow identifying additional genes involved in 
FSHD pathogenesis, as it has happened in other 
complex genetic diseases such as Alzheimer’s disease 
or amyotrophic lateral sclerosis [11-17]. These critical 
aspects must be considered both in research and in 
clinical practice. 
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THE CLASSICAL PHENOTYPE OF FSHD 
 The disease was firstly reported in 1862 by 
Duchenne de Boulogne, who published a picture of an 
affected patient in his Album de photographies 
pathologiques [18]. Duchenne described the disease in 
his famous series of papers in Archives of General 
Medicine in 1869 [19], which is often cited as the 
earliest reference of FSHD [20]. In 1885, Landouzy and 
Dejerine [21] described in detail the clinical features of 
FSHD, thus also called “Landouzy-Dejerine form of 
muscular dystrophy”, characterized by progressive 
facial, shoulder girdle and pectoral muscle weakness 
and atrophy, subsequent involvement of abdominal 
muscles with lumbar hyperlordosis and anterior leg 
muscles with steppage gait. Subsequently, in 1982, the 
thesis of Padberg provided the first modern clinical 
description of FSHD families. Padberg investigated a 
group of 107 subjects from 19 families, including 73 
subjects displaying clinical signs of FSHD. These 
studies provided the first evidence for wide clinical 
variability in FSHD patients, even within the same 
family [22]. 
 The clinical presentation in FSHD is characterized 
by initially restricted distribution of weakness starting 
with asymptomatic facial weakness followed by 
weakness of scapular fixator, humeral, truncal and 
lower extremity muscles. The onset at lower-extremity 
is often characterized by distal weakness, typically in 
the anterior leg compartment, presenting with footdrop. 
Extraocular and bulbar muscles are typically spared. 
Weak abdominal muscles result in a protuberant 
abdomen and contribute to the lumbar lordosis. Lower 
abdominal muscles are weaker than upper abdominal 
muscles, causing strikingly positive Beevor’s s sign, a 
physical finding fairly specific for FSHD [23]. A notable 
distinctive feature of FSHD is that muscle weakness 
displays asymmetric distribution, which does not 
correlate with the handedness of the individual [24]. 
The creatine kinase (CK) level can be moderately 
increased or normal. Electromyography (EMG) and 
histological analysis reveal non-specific myopathic 
changes associated, in some cases, with neurogenic 
and/or inflammatory aspects [25, 26]. Muscle magnetic 
resonance imaging (MRI) can detect muscles showing 
normal MRI signal together with muscles showing 
abnormalities on T1-weighted MRI sequences, 
corresponding to areas of fatty fibrous replacement, or 
areas characterized by increased signal on T2- short 
tau inversion recovery (T2-STIR) sequences also in 
muscles not yet replaced by fat tissue, reflecting an 
increase in tissue water content due to muscle oedema 
[27]. Ancillary features, such as sensorineural deafness 
or retinal vasculopathy have been also reported in 
infantile FSHD forms, but they are not to be considered 
decisive criteria for FSHD diagnosis [28, 29]. FSHD 
has been considered a fully penetrant autosomal 
dominant disease with age-dependent penetrance 
estimated to be >95% by age 20 [30]. However, in 
contrast with the expected course for a classical 
autosomal dominant Mendelian disorder, the 
chronology of disease progression is unpredictable,  
 
and disease expressivity ranges from subjects with 
very mild muscles weakness, almost unaware of being 
affected, to wheelchair-dependent patients (Fig. 1). 
DEFINITION OF DIAGNOSTIC CRITERIA FOR 
FSHD IN PRE-MOLECULAR ERA 
 In 1991 an International Consortium established the 
clinical, laboratory and genetic criteria for FSHD 
diagnosis, in absence of a diagnostic DNA test. This 
work responded for the need of selecting families that 
could be included in the linkage analysis [31] towards 
the identification of the FSHD gene. Four main criteria 
were identified: (1) onset of the disease in facial or 
shoulder girdle muscles; sparing of the extra-ocular, 
pharyngeal and lingual muscles and the myocardium; 
(2) facial weakness in more than 50% of the affected 
family members; (3) autosomal dominant inheritance in 
familial cases; and (4) evidence of myopathic disease 
in EMG and muscle biopsy in at least one affected 
member. By contrast, (1) involvement of extra-ocular, 
masticatory, pharyngeal and lingual muscles; (2) 
regression of symptoms and signs; (3) presence of 
severe and diffuse contractures; (4) involvement of 
myocardium with presence of cardiomyopathy; (5) 
persistently high CK values above five times the upper 
limit, were considered suggestive of alternative 
diagnosis [31]. 
THE DISCOVERY OF DNA ALTERATIONS 
ASSOCIATED WITH FSHD 
 The need for an accurate pre-symptomatic test led 
to an active search for the identification of the FSHD 
gene [30]. In 1990 the FSHD locus was assigned to 
chromosome 4 by positional mapping performed in 10 
Dutch families with autosomal dominance inheritance 
[32]. This chromosomal position was confirmed using 
additional polymorphic markers in other families [33, 
34]. Subsequently, Wijmenga and coworkers [35] 
reported that D4S139, a Variable Number Tandem 
Repeat structure (VNTR) locus, was the most closely 
linked to FSHD. Because D4S139 represents the most 
telomeric 4q-specific marker, it established the location 
of the FSHD gene in the subtelomeric region of 
chromosome 4q. The assignment of the FSHD locus to 
region 4q35 was definitively established in 1992 by six 
laboratories, based on the genotyping of 504 affected 
patients and 559 unaffected subjects from 65 families 
[36]. Later, Wijmenga and coworkers [37] identified a 
3.3 kb tandemly repeated sequence (D4Z4) located at 
the 4q subtelomeric region that could be detected by 
hybridization of EcoRI digested DNA using the p13E-11 
DNA sequence as probe. This study included 11 Dutch 
families, 6 de novo cases, 29 healthy individuals. One 
family presenting compound heterozygosity for two 
D4Z4 alleles smaller than 28 kb was excluded from the 
study. The authors showed that in healthy individuals 
the majority (72%) of EcoRI fragments detected by the 
p13E-11 probe were larger than 28 kb, while in FSHD 
patients there was an overrepresentation of fragments 
smaller than 28 kb [37]. It was also shown that 5 out of  
 







































Fig. (1). Wide variability of clinical expression in a FSHD family. The proband (aged 66 years, Fig. 1A), her brother (aged 
60 yrs, Fig. 1.B1, 1.B2, 1.B3), her sisters (respectively aged 65 and 52 yrs; Fig. 1.C1, 1.C2, 1.C3 and Fig. 1.E1, 1.E2, 1.E3) and 
her son (aged 42 yrs, Fig. 1.D1, 1.D2, 1.D3), all carrying a 23 kb 161qA DRA. The family members 1.A, 1.B, 1.C, 1.D display 
facial weakness (Fig. 1.A1, 1.B1, 1.C1, 1.C2, 1.D1), limitation in raising the arms (the Fig. 1.A2, 1.B3, 1.C3, 1.D3 show the 
maximum capacity of arms abduction), scapula winging (Fig. 1.B3, 1.C3, 1.D3), fulfilling the clinical diagnostic criteria of FSHD 
The sister, 1.E, aged 52 yrs, is asymptomatic. Mild scapula winging is detected at clinical examination (Fig. 1.E2) without any 
motor impairment (Fig. 1.E1, 1.E3). 
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6 affected individuals with unaffected parents carried a 
de novo p13E-11 allele smaller than 28 kb. On this 
basis it was proposed that FSHD is caused by DNA 
rearrangements of p13E-11 EcoRI alleles. However, 8 
healthy individuals presented in the study carried p13E-
11 alleles smaller than 28 kb, providing an early clue 
that D4Z4 allele size alone would be unlikely to explain 
all cases of FSHD pathogenesis. 
THE D4Z4 LOCUS 
 The probe p13E-11 detects a highly polymorphic 
locus with a VNTR structure constituted by a tandemly 
arrayed sequence of DNA repetitive elements named 
D4Z4 [38]. The variation in size of EcoRI fragments is 
due to variability in the number of D4Z4 repeats [39]. In 
normal subjects the p13E-11 EcoRI alleles usually 
range from 40 kb to approximately 300 kb (>10 D4Z4 
units), whereas alleles of 35 kb or shorter (≤ 8 D4Z4 
units) are present in the majority of either de novo or 
familial FSHD patients [40-42]. 
 The D4Z4 repeats belong to a family of 3.3 repeats 
scattered within the human genome including 
chromosome 1 secondary constriction, and the 
heterochromatin of the acrocentric chromosomes [38, 
43, 44]. Importantly, an almost identical D4Z4 array 
was located at chromosome 10q, with 98% homology 
between 4q35 and 10q26 regions [45]. The homology 
between 4q35 and 10q26 is not confined to the 3.3-kb 
repeats but extends both proximally (42 kb) and distally 
to include the telomere [46]. Notably, the size of D4Z4 
alleles on chromosome 10 overlaps with those on 
chromosome 4.  
 The presence of a polymorphism on the D4Z4 copy 
on chromosome 10, creating a BlnI restriction site, has 
facilitated the distinction between 4q and 10q D4Z4 
alleles by using EcoRI/BlnI double digestion followed 
by p13E-11 Southern hybridization [47] (Fig. 2). This 
approach has led to the discovery that in 20-30% of the 
population translocated 4-type repeats reside on 
chromosome 10q and, viceversa, translocated 10-type 
repeats on chromosome 4q [48-51]. De novo reduced 
allele account for a surprisingly high percentage of 
FSHD patients (10%−33%) [52, 53]. This high 
incidence can be partly explained by the presence of 
parental mosaicism for 4q short alleles that has been 
reported in 19% of de novo cases [54-56]. The 























Fig. (2). Schematic representation of Polymorphisms at the 4q and 10q subtelomeres. Schematic representation of the 
method used to calculate D4Z4 repeat numbers from EcoRI-fragment sizes. Seven and eight D4Z4 repeats (31-36 kb EcoRI 
fragment size) were defined to be the upper diagnostic range for FSHD. D4Z4 repeat units on chromosomes 4 and 10 can be 
distinguished because all repeats on 10q contain BlnI restriction sites (B), while all D4Z4 repeats on 4q contain XapI restriction 
sites (X). 
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D4Z4 was found in as much as 3% of the general 
population [57]. These observations, demonstrate that 
the D4Z4 array is highly recombinogenic. 
Notwithstanding, only DRAs located at 4q have been 
associated with FSHD regardless of the repeat type 
composition. 
 Despite the identification of the molecular defect 
associated with FSHD, its pathologic effects remain 
largely unknown. Each D4Z4 repeat unit harbors GC-
rich sequences, which are predominantly found in 
heterochromatic regions of the genome [38, 43] This 
led to the hypothesis that deletion of D4Z4 repeats 
might modify the chromatin organization of the 4q 
subtelomeric region and alter gene expression [43]. 
Consistently, an element within D4Z4 has been shown 
to behave as a silencer that provides a binding site for 
a transcriptional repressing complex [58]. More recent 
findings raise the possibility that epigenetic markings 
like DNA methylation [59], histone modifications [60] or 
chromosomal architectures [61] can be altered at the 
disease locus, suggesting that the chromosomal 
context in which the D4Z4 deletions arise can be 
considered crucial for clinical development of FSHD. A 
recent study indicates that the Polycomb group of 
epigenetic repressors targets D4Z4 in healthy subjects 
and that D4Z4 deletion is associated with reduced 
Polycomb silencing in FSHD patients. Cells from FSHD 
patients produce a chromatin-associated noncoding 
RNA, DBE-T, which recruits the Trithorax group protein 
Ash1L to the FSHD locus, driving histone H3 lysine 36 
dimethylation, chromatin remodeling, and 4q35 gene 
transcription [62]. Collectively, these results suggest a 
model in which reduction of D4Z4 leads to the 
inappropriate transcriptional derepression of proximal 
chromosome 4-specific genes. Indeed, 4q35 proximal 
genes such as FSHD Region Gene 2 (FRG2), FSHD 
Region Gene 1 (FRG1), and Adenine Nucleotide 
Translocator 1 (ANT1), with high myopathic potential, 
were observed to be transcriptionally upregulated in 
FSHD muscle [58] and mice over-expressing FRG1 
develop a muscular dystrophy with features of human 
disease [63]. Involvement of the proximal 4q35 genes 
added a different level of complexity on FSHD 
molecular mechanism other than repeats reduction, 
which indeed does not account for all FSHD cases. 
However, different studies testing this model showed 
controversial results. Some were in accordance [58, 
64-66], while others not [67-69] preventing a 
consensus regarding whether protein-coding genes 
within 4q35 are upregulated and contribute to FSHD 
pathogenesis. 
 Another potential mechanism was suggested when 
detailed sequence analysis revealed that the D4Z4 
repeat contains an open reading frame (ORF) encoding 
a double-homeobox transcription factor, DUX4 [38, 70]. 
It has thus been proposed that reduction of the D4Z4 
array results in the transcription of the DUX4 [71]. 
 Although the abundance of the DUX4 mRNA and 
protein results is extremely low (approximately 1 in 
1000 FSHD muscle cell nuclei were detected with an 
abundant amount of DUX4 mRNA) [72], it has been 
observed that the DUX4-expressing FSHD muscle 
nuclei show pathologic features consistent with DUX4 
induced toxicity [73]. Thus, according to the current 
pathogenic model of FSHD, the inefficient chromatin-
mediated repression, either related to the contraction of 
the array or to its hypomethylation, may result in the 
occasional escape from repression in muscle cells with 
a consequently inappropriate expression of DUX4 
protein [71]. 
 In addition gene expression analyses revealed 
alterations in FSHD muscle that could be linked to 
various pathologic processes such as altered 
angiogenesis, susceptibility to oxidative stress and 
abnormal muscle differentiation [67-69, 74]. Despite all 
these efforts the FSHD pathophysiology and the 
sequence of molecular events associating a potentially 
cytotoxic lesion at muscle level are still elusive. 
THE IDENTIFICATION OF SPECIFIC HAPLO-
TYPES ASSOCIATED WITH D4Z4 REDUCED 
ALLELES 
 Since there are individuals with DRA that do not 
have clinical signs of FSHD, it has been proposed that 
additional DNA sequences flanking the D4Z4 repeat 
array are necessary for disease development. In 2002, 
a polymorphic bi-allelic segment of 10 kb distal to D4Z4 
was identified [46]. Of the two allelic forms, 4A and 4B, 
only 4A was found to be associated with FSHD [75]. 
Additional sequence variations, namely Simple 
Sequence Length Polymorphisms (SSLP), were found 
proximal to the D4Z4 repeat. Together with the 4A/4B 
polymorphisms, these SSLPs generate at least 17 and 
8 genetically distinct variants, respectively, at the 
chromosome 4q and chromosome 10q subtelomeres 
[76]. Among these many haplotypes only the common 
variant 4A161 and the rare variants 4A159 and 4A168 
were found associated with D4Z4 reduced alleles in 
FSHD patients. By contrast, D4Z4 reduced alleles 
associated with other haplotypes were not detected in 
the FSHD cases. Finally, a single nucleotide 
polymorphism (SNP) ATTAAA was found in the pLAM1 
sequence of the 4qA alleles that provides a 
PolyAdenylation Signal (PAS) allowing the expression 
of the most distal copy of the DUX4 gene [77]. Thus, it 
has been proposed that the combination of (1) a 
reduction in the number of D4Z4 elements, (2) the 
presence of the 4qA allele, and (3) the PAS in the 
pLAM1 sequence together with the (159/161/168) 
SSLPs represents the molecular signature that defines 
alleles causally related to FSHD. On this basis it has 
been hypothesized that this particular chromosomal 
setting, named 4APAS, causes FSHD through a toxic 
gain of function attributable to the stabilized distal 
DUX4 transcript [77] (Fig. 3). 
MOLECULAR BASIS OF FSHD: PATHOGENIC 
HYPOTHESIS 
 However, as explained below, data coming from 
different genotype-phenotype studies and clinical 
reports on FSHD patients and families showed that 
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exceptions that are not inconsistent with this 
hypothesis are frequent in human populations. 
LARGE-SCALE POPULATION ANALYSIS 
CHALLENGES THE CURRENT CRITERIA FOR 
THE MOLECULAR DIAGNOSIS OF FSHD 
 The finding of FSHD families with compound 
heterozygosity [6, 78-80] suggests that in the general 
population DRA are more frequent than expected 
based on the prevalence of FSHD (1 in 20,000). This 
possibility was first predicted by van Overveld and 
coworkers [49], who found among 208 anonymous 
blood donors 6 subjects carrying DRA of size between 
25-35 kb. This notion was definitely confirmed by the 
study of 801 normal control subjects from Italy and 
Brazil, which showed that 3% (25 of 801) of normal 
controls carried D4Z4 alleles of size ranging from 21 kb 
(4 D4Z4 units) and 35 kb (8 D4Z4 units) [7]. 
Remarkably 11 of them (~1.3%) carried the supposedly 
pathogenic 4A161PAS haplotype. The age of all these 
healthy carriers ranged between 40 to 78 years, an age 
in which FSHD is considered to be fully penetrant. 
Therefore it can be concluded that the current genetic 
signature of FSHD is a relatively common 
polymorphism and little predictive value can be 
attributed to the 4A161PAS haplotype in the absence 
of family history because 1.3% of healthy subjects 
carry this haplotype [7]. 
FACIOCAPULOHUMERAL MUSCULAR DYS-
TROPHY WITHOUT D4Z4 REPEATS CONTR-
ACTION ON CHROMOSOME 4q35 
 Initially, FSHD patients were shown to exhibit one 





























Fig. (3). Schematic representation of the current view of permissive and not-permissive haplotype. Fig. 3.A: Permissive 
haplotypes. Fig. 3.B: Non-permissive haplotype. The ATTAAA variant creates a polyadenylation signal (PAS) that stabilizes the 
DUX4 transcript and has been postulated to be the critical factor causing FSHD. 
1058    Current Molecular Medicine,  2014, Vol. 14, No. 8 Ricci et al. 
their non-FSHD allele shows, like control alleles, higher 
D4Z4 numbers (n≥ 9-100). Later, the critical number of 
remaining D4Z4 repeats was raised for diagnostic 
purposes (n=9-10) [81, 82]. At the same time it became 
evident that small D4Z4 alleles of 30-40 kb (6–10 D4Z4 
repeats) were found also in normal controls [4-7, 83]. 
Thus, a remarkable overlap exists between D4Z4 
alleles in controls and in FSHD patients and a definition 
of clear cut-off point is difficult. Furthermore it has been 
estimated that approximately 20% of FSHD patients 
carry DRA of 38 kb or larger [7-10], although these 
patients are clinically indistinguishable from those 
carrying a DRA. In 2003 Butz and coworkers 
conducted a systematic study including 37 unrelated 
myopathic patients carrying 32-41 kb D4Z4 alleles (7-
10 units) and 102 healthy controls [83]. A broad 
myopathic spectrum with four phenotypes (typical 
FSHD, facial-sparing FSHD, FSHD with atypical 
features, non-FSHD muscle disease) was found among 
carriers of these alleles termed “borderline”. Seven 
control subjects, out of 102 (6.8%), carried alleles of 
the same size-range. Therefore the study highlighted 
that in this group there is no definite D4Z4 diagnostic 
cut-off point separating FSHD, FSHD-like myopathies 
and controls, thus questioning the clinical significance 
of these “borderline” alleles [83]. 
 More recently, De Greef and coworkers [84] 
performed a cross-sectional study on 33 patients from 
27 families with D4Z4 allele with ≥ 11 repeats. These 
patients, termed the “FSHD2” cohort, displayed D4Z4 
alleles of normal size on both chromosomes 4 alleles 
and appeared clinically undistinguishable from those 
carrying DRA. Of the 33 FSHD2 patients, 20 (61%) 
were males. The average age at onset was 26 years 
(range 0–60), which is almost 10 years later than in 
FSHD1. The initial symptom was scapular weakness in 
61%, foot dorsiflexor weakness was reported in 27%, 
facial weakness in 10%, and hip girdle weakness in 
3%. In contrast with the “FSHD1” cohort, in which there 
are significantly more males clinically and also more 
severely affected than females [10, 85-87] no gender 
difference in disease severity in FSHD2 was observed. 
Furthermore, there is a notable difference in the mode 
of inheritance between FSHD1 and FSHD2. In this 
study [84] pedigree analysis showed that the majority 
of cases (22/33) were sporadic, 11 belonged to 5 
families. Two families showed autosomal dominant 
(parent-child pairs), two families displayed autosomal 
recessive inheritance (sibs pairs) and one family failed 
to present a clear Mendelian pattern of inheritance [84]. 
The major molecular feature of FSHD2 is loss of DNA 
methylation of the D4Z4 arrays at the 4q35 and the 
10q26 [88]. Therefore it has been hypothesized that in 
FSHD2, in which D4Z4 alleles have normal size, there 
is a defect in establishing or maintaining the D4Z4 
repeat chromatin structure. Consistent with this 
hypothesis, mutations in the SMCHD1 (Structural 
maintenance of chromosomes flexible hinge domain-
containing) gene have been found in FSHD2 patients 
[89]. This gene has been recently identified as an 
epigenetic modifier of chromatin structure. It has thus 
been proposed that lower levels of SMCHD1 result in 
lower D4Z4 methylation contributing to disease onset. 
Therefore that lack of autosomal dominant inheritance 
in FSHD2 families would be explained by the presence 
of a mutated gene in association with D4Z4 
hypomethylation. 
GENOTYPE-PHENOTYPE CORRELATION STUDIES 
IN FSHD 
Penetrance of Disease in Carriers of D4Z4 Reduced 
Allele 
 In pre-molecular era, the first observations 
performed on large families with clinical diagnosis of 
FSHD suggested an almost complete penetrance of 
the disease [90-92]. However, since the advent of 
molecular diagnosis for FSHD, subjects carrying DRA 
without signs of disease have been reported [4, 7, 10, 
42, 80, 85-89, 93-95], challenging the notion that DRA 
alone can cause nearly full disease penetrance. 
Several such studies are summarized below. 
 In a previous study on 52 Brazilian families with 
DRA smaller than 35 kb [85], the estimated penetrance 
for FSHD allele was found to be 85% for patients until 
age 30. Furthermore, when the authors considered the 
sexes separately, the estimated penetrance of the 
FSHD allele was significantly greater for males (95%) 
than for females (69%). Interestingly, among 27 
families with at least two clinically affected patients it 
was observed that in 21 families the pattern of 
inheritance was autosomal dominant (4 of them with 
incomplete penetrance). Surprisingly, in 3 pedigrees 
the pattern of inheritance was compatible with the 
presence of an autosomal recessive trait since there 
were at least two affected sibs born from asymptomatic 
parents. These observations suggested that FSHD 
phenotypes may result from distinct types of mutations 
in different families. 
 A study conducted on Italian families [94] reported 7 
subjects, aged 20 to 69 years old, with DRA between 
21 and 37 kb (4-8 units), without symptoms or signs of 
FSHD, who were classified as non-penetrant carriers. 
In this study, unaffected individuals were not observed 
in families with DRA smaller than 20 kb. 
 A retrospective analysis conducted on 85 Japanese 
patients with FSHD and both their parents documented 
parents with DRA who had no clinical symptoms, 
confirming an estimated low penetrance of 59% 
(excluding somatic mosaicism) [95]. 
 Tonini et al. in 2004 [86], analyzing 238 subjects 
with DRA <35 kb from 106 unrelated families, observed 
that about 20% of individuals related to FSHD patients 
who carried a DRA remained asymptomatic or were 
minimally affected with a significantly higher proportion 
of females than males; asymptomatic carriers were 
found in about 30% of the families. 
 Recently, Sakellariou and coworkers [10] reported 
clinical and genetic analysis of 133 individuals carrying 
DRA (71 probands and 62 relatives) from 71 unrelated 
Greek families, revealing a high percentage (almost 
50%) of asymptomatic relatives older than 30 years 
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and carrying DRA. The percentage of unaffected 
carriers was also lower in males than in females (29% 
vs 71%). It is also noteworthy that 16 among the 38 
multiple-case families (42%) were found to have at 
least one symptom-free individual, with a greater 
proportion of asymptomatic or minimally affected gene 
carriers concentrating in some pedigrees, as previously 
observed by Tonini and coworkers [86]. A statistically 
significant association between the genders and the 
clinical manifestation of the disease was also observed: 
among the females the percentage of symptomatic 
patients was found to be 66.7% whereas among the 
males it was 86.6%. 
 The recent study performed by the Italian Clinical 
Network for FSHD [87] evaluated the degree of motor 
impairment in a large group of patients affected by 
facioscapulohumeral muscular dystrophy and their 
relatives who carry DRA. Clinical assessment was 
performed in 530 subjects, 163 probands and 367 
relatives, from 176 unrelated families according to a 
standardized clinical score [96]. Overall, 32.2% of 
relatives did not display any muscle functional 
impairment. This phenotype was influenced by the 
degree of relation with proband, because 47.1% of 
second- through fifth-degree relatives were unaffected, 
while only 27.5% of first-degree family members did not 
show motor impairment. The estimated risk of 
developing motor impairment by age 50 for relatives 
carrying a DRA with 1-3 repeats or 4-8 repeats was 
88.7% and 55% respectively. Male relatives had a 
mean score significantly higher than females (5.4 vs 
4.0, p=0.003). No 4q haplotype was exclusively 
associated with the presence of disease. In 19 (13%) 
families in which DRA with 4-8 repeats segregate, the 
diagnosis of FSHD was reported only in one 
generation. In 5 pedigrees the pattern of inheritance 
was compatible with the presence of an autosomal 
recessive trait since there were at least two affected 
sibs born from asymptomatic parents. 
 Overall these studies on cohorts of FSHD families 
of different geographical origin showed that penetrance 
of disease is not complete, with females significantly 
less affected than males and in some families 
autosomal dominant mode of inheritance is not 
observed. 
ATYPICAL PHENOTYPES ASSOCIATED WITH 
D4Z4 REDUCED ALLELES: CLINICAL SUB-
TYPES OF FSHD OR MORE COMPLEX MYO-
PATHIC CONDITIONS? 
 In the past 20 years, assessment of the D4Z4 array 
size as diagnostic test for FSHD has led to the 
identification of phenotypes that differs at various 
degrees from the original description of disease made 
by Landouzy-Dejerine [21]: two examples are shown in 
Figs. (4, 5). This has provoked a trend towards the 
expansion of the clinical pattern associated with D4Z4 
reduced allele. Several subtypes of FSHD with atypical 
clinical presentation have been described (Table 1) [4, 
83, 97-119]. 
 For example, in 2000 van der Kooi and coworkers 
[102] described six sporadic cases that did not meet 
most of the diagnostic criteria defined in 1991 but were 
diagnosed as FSHD because they carried a DRA 
(range 26 to 38 kb) on 4q. The foot drop was the 
predominant clinical feature found in three patients; in 
three others, inability to walk on toes, shoulder pain, 
and pelvic limb weakness with difficulty in walking were 
reported, respectively. None of them had facial 
weakness and only one complained of shoulder 
weakness. Interestingly, none had a positive family 
history. 
 In the same year, Felice and coworkers [103] 
described 10 patients out of 14, with facial-sparing 
scapular myopathy associated with DRA (range 20 to 
39 kb). Except for the absence of facial weakness, 
most patients had clinical and laboratory features 
otherwise consistent with FSHD. Five patients referred 
also a positive family history of similar weakness, 
although DNA analysis was not performed on other 
family members. 
 Felice and Moore in 2001 [104] also described four 
patients, each harboring DRA (range 25 to 34 kb), who 
presented with atypical phenotypes including facial-
sparing scapular myopathy, limb-girdle muscular 
dystrophy (LGMD) distal myopathy and asymmetric 
brachial weakness. Only the first two patients had 
undergone muscle biopsies, which showed unspecific 
dystrophic features. None of these patients were 
subjected to other molecular investigations for 
differential diagnosis. Interestingly, the patient with 
LGMD phenotype and asymmetric brachial weakness 
did not report a positive family history for 
neuromuscular diseases. In this work, the authors 
concluded that the availability of the DNA test, 
considered as highly sensible and specific, allowed to 
establish definitively the diagnosis without the need for 
the more invasive and less specific muscle biopsy. 
 Krasnianski et al. [109] described three patients 
from a single family (father and two sons) in which a 23 
kb DRA segregated. They showed signs consistent of 
typical FSHD associated with chronic progressive 
external ophthalmoplegia. The oculomotor impairment 
was reported as the initial manifestation of disease 
starting from infancy. The muscle biopsy of the father 
and one child demonstrated prominent myopathic 
changes without ragged red fibers or histopathological 
features of other neuromuscular diseases. The 
absence of singular or multiple deletions of 
mitochondrial DNA apparently excluded a coincidental 
diagnosis of Chronic Progressive External 
Ophthalmoplegia (CPEO) of mitochondrial origin. On 
the other hand, the classic FSHD distribution of the 
muscle weakness had been never described in patients 
with CPEO. The possibility of oculopharyngeal 
muscular dystrophy was not investigated. In the same 
paper [106], the authors further described other two 
familial cases and one sporadic case with facial-
sparing FSHD syndrome associated with D4Z4 
reduced allele (34 and 30 kb allele respectively). 
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 Cardiac involvement, including hypertrophic 
cardiomyopathy, conduction defects and arrhythmia, 
has been reported in subjects carrying a DRA by 
several reports [98-101], although the European Expert 
Group on FSHD in 1991, that defined the Diagnostic 
Criteria for FSHD in pre-molecular era [31], defined that 
“cardiomyopathy is not part of the disease” and “when 
present it suggests an alternative diagnosis”. 
 Reilich et al. [113] described five unrelated cases 
carrying DRA whose biopsies showed signs of vacuolar 
myopathy with rimmed vacuoles. The atypical clinical 
features included a form of LGMD phenotype with 
facial-sparing, a form of distal and proximal weakness, 
which was associated with dysphagia in one patient 
and a form of a prevalent asymmetric lower limb distal 
weakness. Scapular winging or facial weakness was 
also reported, suggesting the possibility of an 
overlapping FSHD syndrome. In these cases the family 
history was negative for neuromuscular disorders or 
motor impairment, although molecular analysis was not 
performed in other family members. Only in one family 
the DNA testing revealed the same DRA (size 35 kb) in 
the mother and two sisters of the proband affected by 
distal weakness; these relatives showed a mild facial 
involvement at clinical examination. The five muscle 
biopsies of the above unrelated cases showed a 
pattern of degenerative myopathy with rimmed 






























Fig. (4). A myopathic subject and his father, both carriers of a 25 kb 4qA161 DRA. The proband 4.A (19 yrs old) 
complained a mild impairment of the right shoulder girdle. The neurological examination shows mild winged scapula in pushing 
against a wall with the hands at shoulder level and elbows straight (Fig. 4.A2), hypotrophy of right sovrapinatus (Fig. 4.A2) and 
pectoralis muscles (Fig. 4.A1), with no limitation of arm abduction (Fig. 4.A3). Facial weakness is not detected. The neurological 
examination of the father 4.B (59 yrs old) is normal (Fig. 4.B1, 4.B2 and A.B3). 
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chemistry did not detect abnormal desmin, myotilin or 
alphabeta-crystallin deposits, excluding the diagnosis 
of myofibrillar myopathies. Electron microscopy 
revealed autophagic vacuoles containing myelin-like 
material and filamentous nuclear inclusions. 
Interestingly, MRI imaging did not reveal the muscle 
lower limbs involvement typical of FSHD. 
 Table 1 summarizes other several atypical 
phenotypes associated with DRA, including the bent 
spine syndrome, a clinical condition characterized by a 
stooped posture in the standing position, which is 
exaggerated in walking or in exercise and disappears 
in the supine position, sometimes associated with a 
dropped head [107, 110, 115, 116]. The first reported 
case [107] was about a 59-years-old woman with a 
family history of FSHD presenting with an overlapping 
condition with camptocormia, scapular winging and 
mild facial and proximal weakness. Kottlors et al. [115] 
described the case of a 65-years-old man complaining 
of lower back pain and progressive bent spine 
syndrome, since the age of 60, carrying a 31 kb DRA. 
The patient recalled that his mother had a similar 
posture that began at age of 80. The genetic analysis  
 
performed on the available family members revealed 
the presence of DRA in the two daughters, who 
showed signs of myopathic facies. In one slight 
weakness of foot extensors was observed. 
Nonetheless, none in the family presented a typical 
FHSD phenotype. Jordan and coworkers [116] reported 
six sporadic cases carrying a DRA (range 21-34 kb) 
with prevalent axial weakness. All patients referred late 
disease onset in fourth-sixth decades. Muscle MRI 
imaging revealed that in all six patients the most 
severely affected muscles were the thoracic and 
lumbar spinal tract together with hamstrings. 
 The conclusion of some authors is that the 
extensive use of genetic analysis has expanded the 
clinical and morphological spectrum of FSHD, and 
many consider the detection of DRA in a patient 
sufficient to diagnose FSHD [3]. Interestingly, the 
atypical phenotypic cases are often sporadic. It may 
thus be supposed that in these cases the shorter D4Z4 
fragment is not per se sufficient to trigger myopathy. 
Indeed the wide heterogeneity associated with 
alterations on chromosome 4q35 can suggest that 
























Fig. (5). A myopathic subject and his mother, both carriers of a 31 kb 4qA161 DRA. The proband 5.A (29 yrs old) 
complained a mild impairment of the shoulder girdle. The neurological examination shows bilateral winged scapula (Fig. 5.A1) 
and frank pectus excavatum (Fig. 5.A2), with no limitation of arm abduction (Fig. 5.A3); no evident facial weakness is detected 
(Fig. 5.A4). The mother 5.B (63 yrs old) reported congenital hip dysplasia and suffered of scoliosis since infancy (Fig. 5.B1). 
The neurological examination does not show muscle impairment (Fig. 5.B1, 5.B2, 5.B3). 
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Table 1. Synopsis of atypical FSHD patiets and families. 
 
Reference Case Description Family History 
Jardine et al., Neuromuscul Disord 
1994 [97] 
Dominantly inherited muscular dystrophy with onset in the shoulder girdle 
and later progression to the lower limbs, associated with DRA of 38 kb  
Familial cases 
Nakagawa et al., Internal Medicine 
1997 [4] 
6 cases with severe limb and girdle muscular weakness (LGMD-like) with 
or without mild facial muscle involvement (DRA size range: 13 to 24 kb) 
-5 familial cases 
-1 sporadic case 
Laforêt et al., Neurology 1998 [98] 5 FSHD subjects with conduction defects or arrhythmia without associated 
cardiovascular risk factors 
-3 familial cases 
-2 sporadic cases 
Finsterer et al., Cardiology 2005 [99] 
Emmrich et al., Z Kardiol 2005 [100] 
Tsuji et al., Neuromuscular Disorders 
2009 [101] 
3 unrelated subjects with FSHD and cardiomyopathy -2 familial cases 
-1 sporadic case 
van der Kooi et al., J Neurol 
Neurosurg Psychiatry 2000 [102] 
FSHD cases with atypical presentation, characterized by foot drop (3 
cases), shoulder pain and pelvic limb weakness (3 cases). Range of DRA 
size: 26 to 38 kb 
All sporadic 
cases 
Felice et al., Neurology 2000 [103] 10 cases with facial sparing scapular myopathy (range of DRA size: 20 to 
39 kb) 
-5 familial cases 
-5 sporadic cases 
Felice and Moore, Muscle Nerve 2001 
[104] 
1 subject with facial-sparing scapular myopathy (DRA size 25kb), 1 subject 
with limb-girdle muscular dystrophy (LGMD) (DRA size 34kb), 1 subject 
with distal myopathy (DRA size 30kb), and 1 subject with asymmetric 
brachial weakness (DRA size 34 kb) 
-1 familial case 
-4 sporadic cases 
Yamanaka et al., Neurology 2001 [105] 7 subjects with a severe form of FSHD associated with atrophic tongue 
(DRA size range: 10 to 17 kb) 
-2 familial cases 
-3 sporadic cases 
Uncini et al., Neuromuscul Disord 
2002 [106] 
A case with isolated monomelic atrophy of lower limb with calf muscle 
involvement (DRA size 26 kb) 
Familial case  
Umapathi et al., J Neurol Neurosurg 
Psychiatry 2002 [107] 
A case with camptocormia, scapular winging and mild facial and proximal 
weakness 
Familial case 
Krasnianski et al., Arch Neurol 2003 
[109] 
3 subjects from a single family with FSHD and chronic progressive external 
ophthalmoplegia (DRA size 20 kb);  
2 related subjects respectively with facial-sparing scapulohumeral and 
chronic pain/calf atrophy/mild minimal hip flexor paresis (DRA size 34 kb); a 
case with sporadic facial sparing scapulohumeral (DRA size 30 kb) 
-5 familial cases 
-1 sporadic case 
Butz et al., J Neurol 2003 [83] 6 subjects with facial-sparing FSHD, 4 subjects with atypical FSHD (onset 
and predominance in left pelvi-femoral muscle, isolated atrophy M.pect., 
predominant weakness of axial and pelvic girdle, one-sided atrophy of Mm. 
Pect., trap., suprasp.), 4 subjects with no FSHD phenotype (bilateral 
atrophy of Mm. tib. ant., onset in lower limbs with dysarthria and dysphagia, 
discrete facial paresis with highly elevated CK, improvement under cortisol, 





Wood-Allum et al., Neuropathol Appl 
Neurobiol 2004 [110] 
A case with clinical features of FSHD, but also kyphosis, weakness of neck 
flexion, and nemaline rods at muscle biopsy (DRA size 17 kb). A case with 
camptocormia due to weakness in the paraspinal muscles (DRA size 30 kb)  
-1 familial case 
-1 sporadic case 
Sugie et al., Neurology 2009 [111] A case with hemiatrophy (DRA size of 20 kb) Sporadic case 
Zouvelou et al., J Clin Neurosci 2009 
[112] 
A case with persistent, asymptomatic hyperCKemia (DRA size 23 kb) Sporadic case 
Reilich et al., J Neurol 2010 [113] 5 unrelated cases with an unusual phenotype (LGMD phenotype with facial 
sparing, distal and proximal weakness, dysphagia, prevalent asymmetric 
lower limb distal weakness) and vacuolar myopathy with rimmed vacuoles 
-2 possibly 
familial cases 
-3 sporadic cases 
Figueroa et al., J Neurol 2010 [114] 2 siblings, one with isolated facial diplegia and the other with late onset 
facial and limb-girdle weakness (DRA size of 25 kb) 
Familial cases 
Kottlors et al., Muscle Nerve 2010 
[115] 
A case with lower back pain and progressive bent spine syndrome Familial case 
Jordan et al., J Neurol 2011 [116] 6 cases with bent spine syndrome (DRA size range 21 to 34 kb) -2 familial cases 
-4 sporadic cases 
Papadopoulos et al., Muscle Nerve 
2011 [117] 
A case with bent spine syndrome (DRA size 28 kb) Familial case 
Hassan et al., Muscle Nerve 2012 [118] 7 subjects with focal weakness (3 subjects with monomelic lower limb 
atrophy and weakness, 2 subjects with upper limb unilateral weakness or 
atrophy, 2 subjects with axial weakness) 
Familial cases  
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modulate the disease expression, such as epigenetic 
or environmental factors, concomitant inflammatory 
disease. It may plausible that other genetic and/or 
environmental factors may participate in the onset of a 
myopathy that might present clinical features 
overlapping with FSHD. On the other hand, it must also 
be considered the possibility that other myopathies 
might have been misdiagnosed because of the random 
finding of a DRA in the affected subject. 
SEVERAL REPORTS OF “DOUBLE TROUBLE” 
CONDITIONS IN FSHD FAMILIES 
 In 2002, Tonini and coworkers [120] reported two 
unrelated Brazilian families with members apparently 
affected by two different forms of muscular dystrophy. 
In the first one, the 35-years-old male proband showed 
LGMD with proximal weakness, elevated CK (16-fold 
above normal) and a myopathic muscle biopsy. Muscle 
protein immunohistochemical and immunoblotting 
analysis revealed a normal pattern for dystrophin, the 
four sarcoglycans, calpain, dysferlin and telethonin; 
DNA analysis for caveolin-3 gene was negative. Two of 
his sisters also complained of muscle weakness. The 
younger sister, aged 38 years, complained of proximal 
muscular weakness in upper and lower limbs, had calf 
hypertrophy, and a serum CK 5-fold above normal but 
she refused further investigations. The oldest sister, 
aged 51 years, showed mild clinical signs possibly 
consistent with FSHD, confirmed through the molecular 
analysis (30 kb DRA). The DRA was also found in 
another six relatives: four of them, aged 72, 45, 36 and 
22 years, were asymptomatic and two (aged 19 and 16 
years) showed only mild facial hyposthenia. 
Surprisingly the DRA was not detected in the affected 
proband. In the second family, a 57-years-old male with 
a typical FSHD phenotype was carrying a 17 kb DRA, 
which was also present in other affected relatives. 
However, in a 14-year-old severely affected male 
cousin, confined to a wheelchair since age 12, but 
without facial weakness, the small fragment was not 
found; the patient refused to undergo muscle biopsy. 
These families illustrate complicated situations that 
may occur for diagnosis and genetic counseling of 
neuromuscular disorders. Considering that the 
prevalence of hereditary neuromuscular disorders is 
very approximately 1/1000, we estimated that the 
finding of two families with an additional neuromuscular 
disorder was about three times higher than expected. 
Therefore, although the presence of different 
neuromuscular disorders in the same genealogy could 
be only a coincidence, we speculated that some 
epigenetic mechanisms present in particular families 
might turn individuals more prone to pathological 
mutations. 
 However in FSHD, more than in other 
neuromuscular disorders, several “double trouble” 
conditions patients are described. In these patients the 
D4Z4 reduced allele is associated with a well-known 
pathogenic mutation of other genes, causing complex 
and overlapping phenotypes as summarized in Table 2. 
In particular, patients with mitochondrial myopathy/ 
FSHD [121], Becker dystrophy/FSHD [122], Duchenne 
dystrophy/FSHD [123, 124], Leber’s hereditary optic 
neuropathy/FSHD [125], LGMD1C with rippling 
disease/FSHD [126], myotonic dystrophy type 1/FSHD 
[127] were reported suggesting the possibility of a 
synergistic effect of those simultaneous mutations in 
reaching and in modulating the clinical expression. 
 Besides, the coexistence of facioscapulohumeral 
muscular dystrophy and myasthenia gravis in a same 
patient was also reported [128]. 
CONCLUSION 
 In the pre-molecular era, the diagnosis and 
counseling of FSHD families was entirely based on 
clinical evidence [30]. In 1992 the discovery of 
rearranged D4Z4 alleles generated a radical shift in the 
FSHD field [37]. Over the years, DNA testing of the 
D4Z4 locus and flanking polymorphisms has been 
considered highly sensitive and specific and 
extensively used to diagnose FSHD [3] and 
researchers have been trying to explain how 
rearrangements of repetitive elements at the 4q35 
subtelomere might cause disease. Definitively, this 
region represents an important example of how 
repetitive elements can influence gene expression, and 
generates pathology [129]. However, several types of 
evidence challenge the current understanding the 
molecular basis for of FSHD: 1) 20% of FSHD cases 
do not carry alleles with reduced numbers (≤ 8) of 
D4Z4 repeats at 4q35 [7-10] and not all of them can be 
explained by DNA hypomethylation of the D4Z4 array; 
2) alleles with reduced numbers (≤ 8) of D4Z4 repeats 
at 4q35 combined with 4A(159/161/168) PAS 
haplotype, have a frequency of 1.3% among healthy 
subjects from the general population. Thus there are 
millions of individuals carrying this molecular signature 
who do not have FSHD disease [7]; 3) the penetrance 
of the disease among relatives of FSHD patients is 
incomplete and several factors, including the genetic 
background [86, 87], play a role in disease outcome; 4) 
other genetic mechanisms should be considered to 
explain this large percentage of cases in which FSHD 
does not segregate in an autosomal dominant mode of 
inheritance [87] (Fig. 6). 
 All these findings are not surprising if considered 
within the present context of human molecular 
genetics. 
 The extensive use over the past 20 years of DNA 
analysis for studying Mendelian disorders has revealed 
many disease mechanisms that are more complex than 
single mutations. For example, identical phenotypes 
may be produced by mutations in different genes [130], 
the same mutation can cause different phenotypes 
[131, 132], and distinct mutations in the same gene 
may result in different disorders that segregate with 
diverse Mendelian or even multifactorial patterns [133]. 
In addition, the incomplete penetrance of some 
mutations argues for the role of modifying loci or 
epigenetic mechanisms influencing the clinical 
expression in many Mendelian disorders. Moreover the 
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possibility of conducting extensive studies in different 
human populations has revealed the large variability of 
human DNA variations blurring the distinction between 
a polymorphism and a detrimental mutation more 
subtle. Thus, establishing the value of mutational 
events underlying genetic diseases may be complex 
even in diseases with simple patterns of inheritance 
and well-characterized pathologic course [7, 134, 135]. 
Table 2. Synopsis of documented genetic comorbities associated with the FSHD. 
 
Reference Molecular and Clinical Findings 
Lecky et al., Neuromuscul Disord 1991 [123] Duchenne dystrophy  FSHD 
Chuenkongkaew et al., Eur J Neurol 2005 [125] Leber’s hereditary optic neuropathy (G11778A mutation mutation in mitochondrial DNA) / FSHD (DRA size 17-27-kb) 
Korngut et al., Neuromuscul Disord 2008 [124] 
Duchenne dystrophy (deletion c.367_368delGT in exon 6 of the dystrophin 
gene)  
FSHD (DRA size 31 kb) 
Rudnik-Schöneborn et al., Neuromuscul Disord 2008 [122] 
Becker dystrophy (donor splice site mutation c.4071+1 G>T in exon 29 of 
the dystrophin gene)  
FSHD (DRA size 28 kb) 
Filosto et al., Neuromuscul Disord 2008 [121] 
Mitochondrial myopathy (heteroplasmic transition T12313C of the 
tRNALeu(CUN)) 
FSHD (DRA size 25 kb) 
Ricci et al., Neuromuscul Disord 2012 [126] LGMD1C with rippling disease (heterozygous CAV3 T78M)  FSHD (DRA size 35 kb) 
Masciullo et al., Neuromuscul Disord 2013 [127] 
Myotonic dystrophy type 1 (CTG expansion at the DMPK locus, about 500 
repeats)  























Fig. (6). Synopsis of findings in 20 years of FSHD genetic studies. The extended use of D4Z4 analysis in FSHD has challenged 
the original notion that FSHD is a fully-penetrant autosomal dominant disease associated with reduction in size of D4Z4 alleles. 
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 FSHD seems to fall in this complex pattern. A wide 
variability in clinical spectrum together with a growing 
number of atypical clinical presentations associated 
with the FHSD genetic marker has been extensively 
documented. Interestingly, several cases are sporadic 
with no clear autosomal dominant inheritance and in 
some families the occurrence of affected sibs with 
healthy parents suggests an autosomal recessive 
mode of inheritance. Different explanations should be 
considered for atypical cases previously considered as 
examples of the wide clinical spectrum of FSHD as well 
as for non-manifesting relatives usually believed 
examples of non-penetrance. First, clinical 
heterogeneity associated with DRA may indicate 
involvement of other mechanisms that influence and 
modulate the disease expression (such as genetic, 
epigenetic or environmental factors), thus emphasizing 
the concept that the current genetic signature of FSHD 
alone may not be sufficient to produce clinical 
symptoms. Second, in families that include 
asymptomatic members and/or atypical phenotypes, 
the significance of the DRA should be carefully 
evaluated, and whole Exome Sequencing or Whole 
Genome Sequencing should be conducted in an 
attempt to identify new susceptibility/causative factors 
contributing to FSHD. To reach this goal, the precise 
phenotypic classification of patients and families as 
well as the natural history of the disease and pattern of 
inheritance will be crucial to create parameters to 
subclassify FSHD patients. This approach will lay the 
basis for a more precise genetic counseling of at-risk 
families and a better understanding of FSHD 
pathogenesis leading to the identification of outcomes 
of interests for patients and clinicians to be used in 
clinical trials. 
ABBREVIATIONS 
FSHD =  Facioscapulohumeral muscular dystrophy 
DRA =  D4Z4 reduced allele 
ORF =  Open reading frame 
LGMD =  Limb Girdle Muscular Dystrophy 
MRI =  Magnetic Resonance Imaging 
CPEO =  Chronic progressive external  
    ophthalmoplegia 
EMG =  Electromyography 
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